Abu Dhabi-based leading healthcare technology company, G42 Healthcare has entered into a partnership with American eCommerce giant Amazon’s cloud unit Amazon Web Services (AWS) in order to develop new global genomics, proteomics, and biobanking service.
The collaboration aims to bring global access to G42 Healthcare’s world-leading next-generation sequencing, proteomics, and data analytics capabilities to governments, population genome programs, and life science initiatives across the world.
The alliance was announced at the BIO International Convention in San Diego, California. According to the statement, “The G42 Healthcare – AWS initiative is about enabling this value swiftly, safely, reliably, and in an affordable way.”
G42 Healthcare owns the region’s largest Omics Centre of Excellence in Abu Dhabi, which can deliver over 500,000 whole-genome sequences per year.
Ashish Koshy CEO – G42 Healthcare
“Our goal with AWS is to take the capabilities that have taken years and significant resources to build, global and at speed. This means working towards what we believe will be a globally first, competitive, immediately deployable, and modular end-to-end service. Our offering aims to leverage the extensive omics data management and bioinformatics solutions hosted globally on AWS at our customers’ fingertips. For us and AWS, this collaboration is about much more than data; it’s about value.”
Mr. Jens Dommel, Head of Public Sector Healthcare, EMEA, Amazon Web Services said that, “The cooperation between G42 Healthcare and AWS is an exciting milestone to provide on-demand service for multi-omics data globally.”
“Governments and researchers can benefit from democratized access to next-generation sequencing, proteomics, and data analytics, supported by the most flexible and secure cloud computing environment available today,” Mr. Dommel added.
